Incyte Corp. (INCY) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1155916,
    "name": "Incyte Corp.",
    "stock_name": "Incyte Corp.",
    "full_name": "Incyte Corp.",
    "name_url": "stocks-analysis/incyte-corp",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "100.46",
    "chg": -0.98,
    "chgp": "-0.97%",
    "dir": -1,
    "prev_price": "101.44",
    "mcapval": "16,903.10",
    "mcap": "Mid Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US45337C1027",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "4.18 M",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/incyte-corp-1155916-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Incyte Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-incyte-corp-overvalued-or-undervalued-3637358",
        "imagepath": "",
        "date": "2025-10-21 12:00:42",
        "description": "As of 17 October 2025, Incyte Corp. has moved from an attractive to a fair valuation grade. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 301, which is significantly higher than the peer average of approximately 22.95. Additionally, the EV to EBITDA ratio stands at 36.85, further indicating a premium valuation compared to industry norms.\n\nIn comparison to its peers, Incyte's Price to Book Value is 3.63, and its EV to Sales ratio is 2.47, both of which suggest that the stock is priced above its fundamental value. Notably, while Incyte has outperformed the S&P 500 in the short term with a 1-year return of 31.82% versus 14.08%, its long-term performance has lagged, with a 5-year return of -3.38% compared to the S&P's 91.29%. This discrepancy reinforces the notion that the stock may be overvalued relative to its growth prospects...."
      },
      {
        "title": "Incyte Corp. Experiences Valuation Adjustment Amid Strong Market Performance and Competitive Positioning",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/incyte-corp-sees-valuation-grade-downgrade-from-attractive-to-fair-amid-price-fluctuations-3640722",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/IncyteCorp_valuationdot_3640722.png",
        "date": "2025-10-20 16:17:02",
        "description": "Incyte Corp., a midcap pharmaceutical company, has adjusted its valuation, with its stock price at $87.57. Over the past year, it has achieved a 31.82% return, outperforming the S&P 500. Key financial metrics indicate competitive positioning within the industry, showcasing resilience amid market dynamics."
      },
      {
        "title": "Is Incyte Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-incyte-corp-overvalued-or-undervalued-3631769",
        "imagepath": "",
        "date": "2025-10-19 11:56:17",
        "description": "As of 17 October 2025, Incyte Corp. has moved from an attractive to a fair valuation grade. The company appears to be overvalued based on its current metrics, with a P/E ratio of 301, a Price to Book Value of 3.63, and an EV to EBITDA of 36.85, all significantly higher than typical industry standards. In comparison, a peer like Incyte Corp. has a fair valuation with a P/E of 22.95 and an EV to EBITDA of 13.36, indicating that Incyte Corp. is trading at a premium relative to its peers.\n\nDespite recent strong performance, with a 1-year return of 31.82% compared to the S&P 500's 14.08%, the significant disparity in valuation ratios suggests that Incyte Corp. may not sustain this momentum in the long term. Overall, the company is overvalued in the current market context...."
      },
      {
        "title": "Is Incyte Corp. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-incyte-corp-technically-bullish-or-bearish-3544979",
        "imagepath": "",
        "date": "2025-09-20 19:00:28",
        "description": "As of 30 July 2025, the technical trend for Incyte Corp. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, and Bollinger Bands also reflect a bullish stance in both time frames. Daily moving averages are bullish, while the KST shows bullish signals weekly and monthly. However, Dow Theory indicates a mildly bearish trend on the weekly chart, contrasting with a mildly bullish monthly view. The On-Balance Volume (OBV) is mildly bearish weekly but bullish monthly.\n\nIn terms of performance, Incyte has outperformed the S&P 500 year-to-date with a return of 24.51% compared to 12.22%, and over the past year with 31.96% against 17.14%. However, over the longer three-year and five-year periods, it has significantly underperformed the benchmark.\n\nOverall, the current technical stance is bullish, driven by strong MACD, Bollinger Bands, and moving averages, despite some mixe..."
      },
      {
        "title": "Is Incyte Corp. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-incyte-corp-overvalued-or-undervalued-3541703",
        "imagepath": "",
        "date": "2025-09-20 17:33:39",
        "description": "As of 30 June 2025, the valuation grade for Incyte Corp. has moved from expensive to fair, indicating a more favorable assessment of its market position. The company appears fairly valued based on its current metrics. Key ratios include a P/E ratio of 301, a Price to Book Value of 3.63, and an EV to EBITDA of 36.85, which suggest that while there are some high valuations, they may be reflective of the company's growth potential in the pharmaceuticals and biotechnology sector.\n\nIn comparison to peers, Incyte Corp. has a fair valuation with a P/E of 22.9465 and an EV to EBITDA of 13.3559, indicating that it is positioned reasonably within its industry. Notably, while Incyte has outperformed the S&P 500 year-to-date with a return of 24.51% compared to 12.22%, its longer-term performance over three and five years shows a decline, suggesting volatility and potential challenges ahead...."
      }
    ],
    "total": 10,
    "sid": "1155916",
    "stock_news_url": "https://www.marketsmojo.com/news/incyte-corp-1155916"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is Incyte Corp. overvalued or undervalued?

2025-10-21 12:00:42

As of 17 October 2025, Incyte Corp. has moved from an attractive to a fair valuation grade. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 301, which is significantly higher than the peer average of approximately 22.95. Additionally, the EV to EBITDA ratio stands at 36.85, further indicating a premium valuation compared to industry norms. In comparison to its peers, Incyte's Price to Book Value is 3.63, and its EV to Sales ratio is 2.47, both of which suggest that the stock is priced above its fundamental value. Notably, while Incyte has outperformed the S&P 500 in the short term with a 1-year return of 31.82% versus 14.08%, its long-term performance has lagged, with a 5-year return of -3.38% compared to the S&P's 91.29%. This discrepancy reinforces the notion that the stock may be overvalued relative to its growth prospects....

Incyte Corp. Experiences Valuation Adjustment Amid Strong Market Performance and Competitive Positioning

2025-10-20 16:17:02

Incyte Corp., a midcap pharmaceutical company, has adjusted its valuation, with its stock price at $87.57. Over the past year, it has achieved a 31.82% return, outperforming the S&P 500. Key financial metrics indicate competitive positioning within the industry, showcasing resilience amid market dynamics.

Is Incyte Corp. overvalued or undervalued?

2025-10-19 11:56:17

As of 17 October 2025, Incyte Corp. has moved from an attractive to a fair valuation grade. The company appears to be overvalued based on its current metrics, with a P/E ratio of 301, a Price to Book Value of 3.63, and an EV to EBITDA of 36.85, all significantly higher than typical industry standards. In comparison, a peer like Incyte Corp. has a fair valuation with a P/E of 22.95 and an EV to EBITDA of 13.36, indicating that Incyte Corp. is trading at a premium relative to its peers. Despite recent strong performance, with a 1-year return of 31.82% compared to the S&P 500's 14.08%, the significant disparity in valuation ratios suggests that Incyte Corp. may not sustain this momentum in the long term. Overall, the company is overvalued in the current market context....

Is Incyte Corp. technically bullish or bearish?

2025-09-20 19:00:28

As of 30 July 2025, the technical trend for Incyte Corp. has changed from mildly bullish to bullish. The weekly and monthly MACD indicators are bullish, and Bollinger Bands also reflect a bullish stance in both time frames. Daily moving averages are bullish, while the KST shows bullish signals weekly and monthly. However, Dow Theory indicates a mildly bearish trend on the weekly chart, contrasting with a mildly bullish monthly view. The On-Balance Volume (OBV) is mildly bearish weekly but bullish monthly. In terms of performance, Incyte has outperformed the S&P 500 year-to-date with a return of 24.51% compared to 12.22%, and over the past year with 31.96% against 17.14%. However, over the longer three-year and five-year periods, it has significantly underperformed the benchmark. Overall, the current technical stance is bullish, driven by strong MACD, Bollinger Bands, and moving averages, despite some mixe...

Is Incyte Corp. overvalued or undervalued?

2025-09-20 17:33:39

As of 30 June 2025, the valuation grade for Incyte Corp. has moved from expensive to fair, indicating a more favorable assessment of its market position. The company appears fairly valued based on its current metrics. Key ratios include a P/E ratio of 301, a Price to Book Value of 3.63, and an EV to EBITDA of 36.85, which suggest that while there are some high valuations, they may be reflective of the company's growth potential in the pharmaceuticals and biotechnology sector. In comparison to peers, Incyte Corp. has a fair valuation with a P/E of 22.9465 and an EV to EBITDA of 13.3559, indicating that it is positioned reasonably within its industry. Notably, while Incyte has outperformed the S&P 500 year-to-date with a return of 24.51% compared to 12.22%, its longer-term performance over three and five years shows a decline, suggesting volatility and potential challenges ahead....

View All News